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Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac disease, involving
changes in ventricular myocardial tissue and leading to fatal arrhythmias. Mutations in desmosomal genes are
thought to be the main cause of ARVC. However, the exact molecular genetic etiology of the disease still remains
largely inconclusive, and this along with large variabilities in clinical manifestations complicate clinical diagnostics.
Case presentation: We report two families (n = 20) in which a desmoglein-2 (DSG2) missense variant c.1003A > G,
p.(Thr335Ala) was discovered in the index patients using next-generation sequencing panels. The presence of this
variant in probands’ siblings and children was studied by Sanger sequencing. Five homozygotes and nine heterozygotes
were found with the mutation. Participants were evaluated clinically where possible, and available medical records were
obtained. All patients homozygous for the variant fulfilled the current diagnostic criteria for ARVC, whereas none of the
heterozygous subjects had symptoms suggestive of ARVC or other cardiomyopathies.
Conclusions: The homozygous DSG2 variant c.1003A > G co-segregated with ARVC, indicating autosomal recessive
inheritance and complete penetrance. More research is needed to establish a detailed understanding of the
relevance of rare variants in ARVC associated genes, which is essential for informative genetic counseling and
rational family member testing.
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Case seriesBackground
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is an inherited cardiac disorder, affecting predominantly
the right and sometimes the left ventricle and is charac-
terized by progressive fibro-fatty replacement of ven-
tricular myocardial tissue [1–5]. Clinical manifestations
include recurrent, typically exercise-related ventricular
arrhythmias, syncope, heart failure and sudden cardiac
death [6–8]. Initial presentation is generally at adoles-* Correspondence: juha.koskenvuo@hus.fi
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(http://creativecommons.org/publicdomain/zecence or young adulthood [3]. Diagnosis is based on
the revised 2010 Task Force Criteria (TFC) by Marcus
et al., establishing complex requirements for right ven-
tricular (RV) function and structure, electrocardiographic
(ECG) findings and genetic or familial background of the
disease [9]. Prevalence in the general population has been
estimated to be from 1:5000 to 1:1000 [10, 11].
Mutations in genes encoding cardiac desmosomal
proteins are the major determinants of ARVC [12].
These include plakophilin-2 (PKP2), desmoplakin
(DSP), desmoglein-2 (DSG2), desmocollin-2 (DSC2)
and plakoglobin (JUP) genes [13]. The mode of inher-
itance is typically autosomal dominant with incom-
plete penetrance and variable expression [14]. Rarele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Overview of the variant filtering scheme. Filters used are listed on
the left, and the number of variants on each step are depicted on the
right. QS = quality score; MAF = minor allele frequency; ExAC = Exome
Aggregation Consortium; HGMD = Human Gene Mutation Database;
1000G = 1000 Genomes Project; BpG = Blueprint Genetics;
ACMG = American College of Medical Genetics and Genomics
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opathy or in conjunction with systemic cutaneous dis-
orders with palmoplantar keratoderma and woolly
hair [15–19]. Recent studies have revealed that car-
diac desmosomal gene mutations also associate with
dilated cardiomyopathy (DCM) phenotype [20, 21].
Mutations in the DSP gene explained 5.5% of DCM
cases in a Finnish study cohort [22].
As much as 30–50% of ARVC patients carry at least
one variant classified as disease causing [23, 24]. How-
ever, molecular genetic diagnostic yield is known to be
highly variable, at least partly due to different variant
classification practices. Variability in clinical manifesta-
tions, reduced penetrance and digenic inheritance, along
with disease modifying lifestyle factors such as exercise
act together in complicating the determination of con-
clusive inheritance patterns [25–28]. End-stage ARVC is
also sometimes difficult to distinguish from DCM, with
significantly overlapping morphology due to left ven-
tricular (LV) involvement and apparent similarities in
molecular genetic etiology [29]. Thus, more research is
needed to reveal a group of genes associated with the
ARVC phenotype, their inheritance patterns, and
genotype-phenotype associations in the disease.
Here, we report two Finnish pedigrees (n = 20) in which
a homozygous DSG2 variant c.1003A > G, p.(Thr335Ala)
co-segregated with ARVC, indicating autosomal recessive
inheritance and complete penetrance. All heterozygous
mutation carriers were healthy in terms of cardiac disease,
even though this variant has been previously described as
disease causing in a heterozygous state.
Case presentation
The index patients of these two families fulfilled the re-
vised diagnostic criteria for ARVC by Marcus et al. [9].
Family history was obtained and pedigrees were drawn.
Our clinicians assessed the adult family members at
Helsinki University Hospital or Päijät-Häme Central Hos-
pital where possible by physical examination, resting 12-
lead ECG, signal-averaged electrocardiography (SAECG),
appropriate laboratory tests and transthoracic echocardi-
ography or cardiac magnetic resonance imaging (MRI).
From those already deceased, we acquired all available
hospital records concerning cardiac diseases. The clinical
diagnoses of the family members were also based on the
2010 TFC. All participants are of Finnish ethnicity.
Molecular genetic studies
Blueprint Genetics carried out genetic testing using tar-
geted sequencing panels utilizing oligonucleotide-selective
sequencing (OS-Seq) [30]. Family 1 proband’s genetic
evaluation was performed using the Pan Cardiomyopathy
Panel, covering 103 genes associated with pediatric and
adult onset cardiomyopathies and their phenocopies.Family 2 proband was genetically evaluated using the
Heart Panel, covering 133 genes associated with cardio-
myopathies and hereditary arrhythmias. An additional file
describes these next generation sequencing (NGS) based
panels in more detail (see Additional file 1). Our variant
filtering scheme is outlined in Fig. 1. We studied the
presence of Thr335Ala in DSG2 in probands’ relatives by
bi-directional Sanger sequencing.
Family screening
We found both probands to be homozygous for the mis-
sense variant c.1003A > G, p.(Thr335Ala), (rs191564916)
in DSG2. In silico predictions for this variant are contra-
dictory, as it is predicted to be damaging by PolyPhen
[31] and Mutation Taster [32] but tolerated by SIFT
[33]. There is one heterozygous carrier of the variant in
the 1000 Genomes Project [34] and a total of 67 carriers
in the Exome Aggregation Consortium database (ExAC,
n = 60,275) [35]. The p.(Thr335Ala) in DSG2 is fairly
common especially among the Finnish population as six
Qadri et al. BMC Medical Genetics  (2017) 18:86 Page 3 of 9of the carriers were from Finland (n(FIN) = 3304). How-
ever, there are no homozygote individuals in the ExAC
control cohorts.
We present five homozygotes and nine heterozygotes
older than 20 years from two families with this variant.
The main clinical characteristics of the subjects are
shown in Table 1. Pedigrees of families 1 and 2 are
demonstrated in Fig. 2.Family 1
Proband (II.3) is a 52-year-old male with clinical suspi-
cion of ARVC. He had recurrent episodes of sustained
ventricular tachycardia (VT) and a collapse, with the on-
set of symptoms at age 42. Electrophysiological study
(EPS) revealed a large scar in the RV wall, and a
hemodynamically unstable VT of right ventricular out-
flow tract (RVOT) origin was inducible. Cardiac MRI
showed no abnormalities at the time of initial investiga-
tions. During the follow-up, RV enlargement was noted,
and mild LV dilatation occurred without changes in sys-
tolic function or wall thickness. RV ejection fraction
(EF) was diminished. Patient has an implantable cardio-
verter defibrillator (ICD), and is treated with beta-
blockers.
Proband’s sister (II.5) is a 54-year-old female with an
initial presentation of acute-onset VT with angina pain
and elevated cardiac markers at age 37. Angiography
reveled a coronary artery stenosis which was thought to
be the culprit lesion, and percutaneous coronary inter-
vention (PCI) was performed successfully. Thereafter,
patient had recurrent events of sustained VT with no as-
sociated cardiac marker elevations and ICD was im-
planted. Patient later suffered an ST-elevation myocardial
infarction with another PCI performed. Catheter ablation
was done with no reduction in arrhythmic episodes.
During the follow up, no change in LV diameter was
noted, but the right ventricle underwent marked dilata-
tion. Patient also suffered an event of ventricular fibrilla-
tion, and was resuscitated. This arrhythmia was thought
to be caused by an old infarct scar. She is treated with
beta-blockers and amiodarone.
Proband’s brother (II.4) is a 53-year-old male with no
history of arrhythmias or other known cardiovascular
disease. In the initial examination, cardiac MRI showed
RV dilatation and microaneurysms in the inferior RV
wall and near the RVOT, with an akinetic zone present
inferiorly in the free wall. Septum was slightly hypoki-
netic and thickened, and in the apical septum there was
signal change suggestive of myocardial fatty infiltration.
Screening of family 1 revealed altogether three homo-
zygotes, six heterozygotes and one wild type individual
(Fig. 2). All family members homozygote for the
Thr335Ala fulfilled the criteria for definitive ARVCdiagnosis, whereas none of the heterozygous carriers
had findings relating to ARVC or any other cardiac dis-
ease. However, one of the index patient’s children (III.2)
has had a collapse of unknown etiology. The wild type
homozygous sibling (II.7) has had paroxysmal atrial
fibrillation. The index patient’s mother, who was an
obligatory heterozygous carrier of the mutation, had
congestive heart failure stemming from myocardial in-
farction and chronic atrial fibrillation.
Family 2
Proband (II.1) is a 56-year-old male with ARVC. He had
an event of acute chest pain at the age of 51 with ele-
vated cardiac markers. Patient was initially treated as
having a non-ST elevation myocardial infarction. Sub-
sequent angiography showed no signs of major coron-
ary artery disease. Thereafter, patient experienced
episodes of sustained monomorphic VT. Cardiac MRI
showed RV dilatation and free wall akinesia. LV was
also dilated and thinning of LV myocardium and hypo-
kinesia was present. VT was inducible in EPS, but cath-
eter ablation was not performed. Diagnostic changes
were not found in endomyocardial biopsy, although im-
munohistochemical stains showed borderline myocardi-
tis by Dallas criteria. Patient has an ICD, and is treated
with beta blockers.
Proband’s brother (II.5) is 59 years old and has a his-
tory of atrial fibrillation, hypertension, hypercholesterol-
emia and three-vessel coronary artery disease with
bypass surgery performed. Initially, cardiac MRI showed
RV free wall microaneurysms, along with an RVOT
aneurysm and apical dyssynchronous contraction (Fig. 3).
RV was also slightly dilated and systolic function was di-
minished. During the follow up in a subsequent MRI, dila-
tation of the RV progressed markedly and the RVOT
aneurysm also enlarged (diameter of 75 mm in axial
plane). LV size and function was in the normal range, al-
though it also underwent dilatation during the follow-up.
Ventricular fibrillation was inducible in EPS, and ICD has
been implanted.
Screening of family 2 revealed in total two homozy-
gotes and three heterozygotes (Fig. 2). Again, both of the
homozygotes fulfilled the criteria for definitive ARVC
diagnosis. Heterozygote carriers had no symptoms relat-
ing to ARVC or any other cardiac disease. Neither of the
index patient’s parents’ medical records showed any
signs suggestive of cardiomyopathy. One of them is an
obligatory heterozygous carrier of the mutation, while
the other may either be heterozygous or homozygous for
the variant.
Discussion and conclusions
Based on the families described in this study and the
family published by Rasmussen et al. (see below) [19],
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Fig. 2 Pedigrees of the two families affected with the c.1003A > G, p.(Thr335Ala) mutation in DSG2. Black-filled symbols represent individuals who
fulfill the 2010 Task Force Criteria by Marcus et al. [9]. Age of the family members and their genotypes are listed below the symbols. Parents of
the affected individuals in family 1 are obligatory carriers of the variant. In family 2, one of them is an obligatory heterozygous carrier, while the
other may either be heterozygous or homozygous for the variant
a
c
b
d
Fig. 3 Cardiac magnetic resonance images of a 59-year-old male homozygote for the Thr335Ala in DSG2 (II.5, family 2). Short-axis (a), axial (b) and
right ventricular outflow tract (RVOT) (c) views of the heart show aneurysmal dilatation of the RVOT (arrows). Maximum dimension of the aneurysm
was 67 mm and right ventricular end-diastolic volume index (RVEDVI) was 109 ml/m2. During follow-up, further dilatation of the aneurysm and the RV
was observed. Four-chamber view shows rare microaneurysms in the right ventricular free wall (arrowheads) (d). LV = left ventricle; RV = right ventricle;
RVOT = right ventricular outflow tract; RA = right atrium; AO = aorta
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Qadri et al. BMC Medical Genetics  (2017) 18:86 Page 7 of 9the p.(Thr335Ala) in DSG2 associates with cardiomyop-
athy only in a homozygous state, as heterozygotes are
considered healthy/not affected. This is consistent with
recessive inheritance pattern. These findings highlight
the importance of careful interpretation of the desmo-
somal variants. It seems that truly informative genetic
counseling may require extensive clinical and genetic
work-up in families with ARVC, especially when a vari-
ant is too common in control cohorts to be fully pene-
trant disease causing as heterozygote.
Rasmussen et al. have identified the same DSG2 variant
in a family in which two brothers had severe ARVC [19].
These brothers were homozygous for the variant whereas
their healthy parents and two healthy siblings were carriers,
suggestive of recessive inheritance. Detailed protein investi-
gations demonstrated that the Thr335Ala variant protein
was expressed and incorporated into desmosomes.
In the literature and open databases, the Thr335Ala in
DSG2 has been reported in ≥15 patients with ARVC
(ClinVar accession SCV000060918) [25, 26, 36–44].
Family segregation is rarely studied in these reports. At
least six individuals with ARVC carried an additional
pathogenic PKP2 variant [36, 37, 40–42]. We have previ-
ously detected the same DSG2 variant as heterozygous
in two patients and as homozygous in one patient. The
homozygous patient was in his twenties with DCM, and
did not carry any other variants considered significant
for the phenotype. One heterozygous carrier was a boy
who suffered sudden cardiac death, and the other was a
female with clinically suspected DCM but who also
carried Arg634His in DSC2 (classified as a variant of un-
known significance).
The Thr335Ala has been reported in DCM patients in
two studies [20, 45]. In the first study the index patient
had DCM, requiring heart transplantation at the age of
45 [20]. His brother was diagnosed with asymptomatic
DCM at the age of 52. In addition to the Thr335Ala,
both brothers carried p.(Glu1833Val) in DSP which is
common in the ExAC reference population and likely
has no effect on phenotype. Another brother (49y) and
their mother’s sister (76y) were also carriers of these
variants and they were both healthy. Two other healthy
siblings (47y and 55y) carried only the Thr335Ala vari-
ant. Therefore, DCM was diagnosed in 33% of the
Thr335Ala carriers in the family. Other genetic factors
were recognized that probably had a role in disease
penetrance. In the other study, a DCM patient had both
the Thr335Ala in DSG2 and Ala897fs*4 in DSC2 [45].
However, the DSC2 variant is unlikely to contribute to
the phenotype, as it is also common in the ExAC data-
base and the frameshift leads to a stop codon in the nor-
mal position.
There have also been other homozygous DSG2 vari-
ants such as the p.(Val55Met) found in a DCM patient[46]. His parents were both carriers of the mutation but
only the father had DCM. However, the father’s disease
had later onset and a milder course. Immunostaining
and electron microscopy of explanted LV wall myocar-
dium from the homozygous proband revealed pale inter-
calated discs and significantly shorter desmosomes
compared to wild-type myocardium. Unfortunately, no
heterozygous carrier was studied by immunostaining.
Severe disease in a patient with homozygous DSG2 mu-
tation and a milder disease in a carrier may indicate a
dosage effect of DSG2 mutations on cardiac function.
Variant interpretation is still challenging as earlier
studies form major pitfalls by false classifications related
to small reference populations, co-incidental segrega-
tions and evaluation of only a small subset of the poten-
tially meaningful genes behind a patient’s phenotype. In
diagnostic laboratories and clinics, variant classification
practices are largely based on recommendations by the
American College of Medical Genetics and Genomics
(ACMG) [47]. Without available family segregation data,
variants are classified as pathogenic only when the geno-
type has been identified in a certain number of patients
(e.g. 5–20) with the appropriate phenotype, or when the
variant has occurred de novo multiple times in associ-
ation with sporadic disease. Segregation analyses of large
families are considered the best approach to define
causativity of a variant and assess its penetrance. Large-
scale genetic research and variant sharing will eventually
bring more consistency to the evaluation of families with
inherited cardiac diseases.Additional file
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